Diana Scherer - Glaukos Corp VP Counsel

Glaukos Corp Management Efficiency

The company has return on total asset (ROA) of (0.0774) % which means that it has lost $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.261) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.16 in 2024. At this time, Glaukos Corp's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 22.4 M in 2024, whereas Other Assets are likely to drop slightly above 15.3 M in 2024.

Similar Executives

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. Glaukos Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 727 people. Glaukos Corp (GKOS) is traded on New York Stock Exchange in USA. It is located in One Glaukos Way, Aliso Viejo, CA, United States, 92656 and employs 907 people. Glaukos Corp is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Glaukos Corp Leadership Team

Glaukos Stock Performance Indicators

Additional Tools for Glaukos Stock Analysis